Status
Conditions
Treatments
About
RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult
Loading...
Central trial contact
Marte S Heiberg, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal